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ORIGINAL ARTICLE
Endogenous Levels of Circulating Androgens and Risk of Crohn’s
Disease and Ulcerative Colitis Among Women: A Nested
Case–Control Study from the Nurses’ Health Study Cohorts
Hamed Khalili, MD, MPH,* Ashwin N. Ananthakrishnan, MD, MPH,* Gauree G. Konijeti, MD, MPH,*
Leslie M. Higuchi, MD, MPH,† Charles S. Fuchs, MD, MPH,‡,§ James M. Richter, MD,*
Shelley S. Tworoger, PhD,§,jj Susan E. Hankinson, ScD,§,jj,¶ and Andrew T. Chan, MD, MPH*,§
Background: Androgens, which are known to be altered by exogenous hormone use, have recently been linked to alterations of the gut microbiome
and mucosal immune function. No study has evaluated the association between circulating levels of androgens and risk of Crohn’s disease (CD) and
ulcerative colitis (UC).
Methods: We conducted a nested case–control study of women enrolled in the Nurses’ Health Study and Nurses’ Health Study II who provided a blood
specimen. Cases of CD and UC were each matched to 2 controls. Prediagnosis plasma levels of dehydroepiandrosterone sulfate, testosterone, and sex
hormone–binding globulin were measured. We examined the association of each analyte with risk of CD or UC using conditional logistic regression models.
Results: Compared with women in the lowest quintile of testosterone, the multivariable-adjusted odds ratios for CD were 0.86 (95% conﬁdence
interval, 0.39–1.90) for women in the second quintile, 0.49 (95% conﬁdence interval, 0.21–1.15) for the third quartile, 0.22 (0.08–0.65) for the fourth
quintile, and 0.39 (95% conﬁdence interval, 0.16–0.99) for the highest quintile (Plinear trend ¼ 0.004). In contrast, we did not observe a consistent
association between prediagnostic testosterone and risk of UC (Plinear trend ¼ 0.84). We also did not observe any association between plasma levels of sex
hormone–binding globulin or dehydroepiandrosterone sulfate and risk of UC or CD (all Plinear trends . 0.10).
Conclusions: Among women, prediagnostic circulating testosterone is associated with a lower risk of CD but not UC. Further studies to understand the
biological mechanisms by which endogenous androgens may mediate the etiopathogenesis of CD are warranted.
(Inﬂamm Bowel Dis 2015;21:1378–1385)
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C rohn’s disease (CD) and ulcerative colitis (UC), collectivelyknown as inﬂammatory bowel disease (IBD), are chronic
inﬂammatory disorders of the gastrointestinal tract affecting
nearly 1.4 million Americans. Although the exact pathophysiol-
ogy of the disease remains largely unknown, it is thought that IBD
occurs as a result of inappropriate immune response to the
intestinal microbiome in genetically susceptible individuals.1 In
turn, the composition of human gut microbiome seems to be
Received for publication December 13, 2014; Accepted February 4, 2015.
From the *Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; †Division of Gastroenterology and Nutrition,
Boston Children’s Hospital and Harvard Medical School, Boston, Massachusetts; ‡Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts;
§Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts; jjDepartment of Epidemiology, Harvard
School of Public Health, Boston, Massachusetts; and ¶Division of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts.
Supported by R01 CA137178, R01 CA050385, P01 CA87969, CA49449, CA67262, P30 DK043351, K23 DK099681, K08 DK064256, K24 098311, and K23
DK091742. A. T. Chan is supported by a senior investigator grant from the Crohn’s and Colitis Foundation of America. H. Khalili is supported by a career development
award from the American Gastroenterological Association and by the National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK099681). L. M. Higuchi is
supported by National Institute of Diabetes and Digestive and Kidney Diseases (K08 DK064256).
A. N. Ananthakrishnan is a member of the scientiﬁc advisory board for Prometheus, Inc., and Janssen, Inc., Abbvie, and Cubist Pharmaceuticals. J. M. Richter is
a consultant for policy analysis. A. T. Chan has served as a consultant for Bayer Healthcare, Pﬁzer, Inc., and Pozen, Inc. The remaining authors have no conﬂicts of interest to
disclose.
The institutional review board at the Partners Healthcare and Brigham and Women’s Hospital approved this study.
Requests for access to data, statistical code, questionnaires, and technical processes may be made by contacting the corresponding author at hkhalili@mgh.harvard.edu.
Reprints: Hamed Khalili, MD, MPH, Digestive Healthcare Center, Crohn’s and Colitis Center, Massachusetts General Hospital, 165 Cambridge Street, 9th Floor, Boston,
MA 02114 (e-mail: hkhalili@mgh.harvard.edu).
Copyright © 2015 Crohn’s & Colitis Foundation of America, Inc.
DOI 10.1097/MIB.0000000000000385
Published online 3 April 2015.
1378 | www.ibdjournal.org Inﬂamm Bowel Dis  Volume 21, Number 6, June 2015
closely linked to environmental factors, such as diet, stress, and
medications.2–4
Genetic studies have identiﬁed a number of common
variants associated with risk of CD and UC.5–7 Collectively, the
contribution of these variants to risk of IBD is modest. Therefore,
identiﬁcation of novel exogenous and endogenous factors with
potential biological links to human immune function and/or the
microbiome will likely better shape our overall understanding of
the complex interplay of the environment and genetics on risk of
CD and UC. An association between oral contraceptives (OCs)
and risk of CD has been consistently demonstrated.8 Recently, we
conﬁrmed this association in 2 prospective cohorts of women.9 In
addition, we have also shown an association between use of men-
opausal hormone therapy (MHT) and risk of UC.10 Although the
exact biological mechanism underlying these associations is
unknown, these medications are known to inﬂuence endogenous
circulating levels of sex hormones.11–13 In turn, compelling data
have linked these hormones to immune function and/or gut micro-
biome composition and function.14,15 To date, no studies have
evaluated the association between endogenous sex hormones
and risk of CD or UC.
We therefore sought to examine the association between
prediagnostic levels of circulating androgens and risk of CD and
UC in 2 large ongoing prospective cohort studies of U.S. women,
the Nurses’ Health Study (NHS) and NHSII. With more than 20
years of biennially updated and validated data on use of OC, men-
opausal hormones, diet, and medical diagnoses, as well as archived
blood specimens, these cohorts offered us the unique opportunity to
examine the association between prediagnostic measures of plasma
androgens and subsequent risk of CD and UC.
METHODS
Study Population
The NHS is a prospective cohort that began in 1976 when
121,700 U.S. female registered nurses, aged 30 to 55 years,
completed a mailed questionnaire. Follow-up questionnaires are
mailed every 2 years to update health information. In 1989,
a parallel cohort, the NHS II, enrolled 116,430 U.S. female nurses
between the ages of 25 and 42 years. These women have been
followed with similar biennial questionnaires. Follow-up for these
participants has consistently exceeded 95%.
In 1989 to 1990, 32,826 NHS participants (aged 43–69 yr)
returned a blood sample on ice packs by overnight courier and
completed a short questionnaire.16 Between 1996 and 1999,
29,611 NHSII participants (aged 32–54 yr) provided blood sam-
ples and completed a short questionnaire in a similar protocol.17
Blood samples were processed on receipt and subsequently stored
in the vapor phase of liquid nitrogen freezers. Our study is a nested
case–control study of women with available blood samples in the
2 large prospective cohorts of NHS and NHSII. Institutional
review board at the Brigham and Women’s Hospital approved
this study.
Ascertainment of Cases and Controls
We have previously detailed our methods for conﬁrming
self-reported cases of CD and UC.9,18,19 In brief, since 1976,
participants have reported diagnoses of UC or CD through an
open-ended response on biennial surveys. In addition, participants
were asked about diagnoses of UC since 1982 and CD since 1992.
In NHS II, we have speciﬁcally queried participants about diag-
noses of both CD and UC since 1993. When a diagnosis was
reported on any biennial questionnaire, a supplementary question-
naire and related medical records were requested and reviewed by
2 gastroenterologists blinded to exposure information.
We excluded participants who subsequently denied either the
diagnosis on the supplementary questionnaire or permission to
review their records. Data were extracted on diagnostic tests,
histopathology, anatomical location of disease, and disease behav-
ior. Using standard criteria,20–23 UC diagnosis was based on a typ-
ical clinical presentation for .4 weeks and endoscopic or surgical
pathological specimen consistent with UC (e.g., evidence of coli-
tis). CD diagnosis was based on a typical clinical history for .4
weeks and endoscopy or radiologic evaluation demonstrating small
bowel ﬁndings, or surgical ﬁndings consistent with CD combined
with pathology suggesting transmural inﬂammation or granuloma.
Disagreements were resolved through consensus. Among those
women from whom we received adequate medical records, the case
conﬁrmation rate for IBD was 78%.9
From among participants who provided a blood specimen,
we matched 83 CD cases (NHS ¼ 59, NHSII ¼ 24) and 91 UC
cases (NHS ¼ 59, NHSII ¼ 32) that were diagnosed after blood
collection to 2 controls on age, menopausal status at the time of
blood collection, month of blood collection, fasting status, and use
of MHT at the time of blood collection. In NHSII, premenopausal
blood samples that were timed to the luteal phase of the menstrual
cycle were also matched on the day of the luteal phase (date of
next period minus date of blood draw). Consistent with previous
studies, we identiﬁed and excluded 2 outliers: 1 control with
a dehydroepiandrosterone sulfate (DHEAS) ,15 mg/dL and 1
control with a testosterone ¼ 4.5 ng/dL.24 Thus, our ﬁnal analysis
included 83 CD cases matched to 165 controls and 91 UC cases
matched to 181 controls.
Ascertainment of Exposures
Our primary exposures of interest were androgens,
which included testosterone, DHEAS, and sex hormone–bind-
ing globulin (SHBG). All laboratory assays were conducted by
personnel blinded to case–control status at the Mayo Clinic
(Rochester, MN). Samples were assayed for testosterone in 3
batches by liquid chromatography–tandem mass spectrometry;
DHEAS and SHBG were measured by a solid-phase, chemi-
luminescent enzyme immunoassay (Siemens Healthcare
Diagnostics, Deerﬁeld, IL). Masked replicate quality control
samples (10% of the samples) were included in each batch to
assess coefﬁcients of variation. Overall coefﬁcients of varia-
tion within batches were 6.4% to 9.6% for DHEAS, 4.0% to
5.1% for testosterone, and 4.3% to 6.3% for SHBG. Free
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testosterone was calculated using the formula described by
Södergard et al.25
Assessment of Other Covariates
On each biennial questionnaire, women were asked about
pertinent lifestyle factors, including body weight, smoking status,
parity, and use of OCs and MHT. Participants’ self-report of body
weight, height, and use of OCs have been previously vali-
dated.26,27 At baseline, we collected data on age at menarche in
both cohorts. On each questionnaire, menopausal status was deter-
mined by asking whether the participants’ menstrual periods had
ceased permanently and, if so, at what age and for what reason
(occurring naturally or after radiation therapy or surgery). If men-
opause was due to surgery, the participant was asked to report the
number of ovaries removed. Self-reported type of menopause and
age at time of menopause was highly accurate compared with
medical records.28
Information on physical activity was also collected every 2
to 4 years. Participants’ self-report of physical activity and use of
OC have been previously validated.26,27 Intake of dietary vitamin
D was assessed using validated, self-administered, semiquantita-
tive food frequency questionnaires administered in 1991, 1995,
and 1999 in NHSII and 1984, 1986, and 1990 in NHS before
blood collections. For these analyses, data on weight and meno-
pause status were taken directly from the short questionnaires
administered at the time of blood collection; data from other co-
variates were obtained from the general questionnaires that were
completed closest to the time of blood draw.
Statistical Analysis
We examined the possibility that there is a nonlinear
association between androgens and risk of CD and UC using
a previously reported nonparametric cubic spline method.29 This
method is unique in allowing for controlling for covariates. It also
allows stepwise selection among spline variables. The output is the
set of P-values from the likelihood ratio tests for nonlinearity,
a linear relation, and any relation, as well as a graph of the predicted
incidence rate, with or without its conﬁdence band. Using this
method, the likelihood ratio test comparing models with linear
terms with those with spline terms were not statistically signiﬁcant
(All Pcomparisons . 0.40), indicating that the relationship between
androgens and risk of CD and UC is linear. As these analyses are
particularly sensitive to outliers, we performed further sensitivity
analyses removing observations beyond 3 interquartile ranges. In
these analyses, the likelihood ratio test comparing models with
linear terms with those with spline terms continue to not be statis-
tically signiﬁcant (All Pcomparisons. 0.30). Based on these ﬁndings,
we used continuous and quintile categories of androgens in our
main analyses.
We calculated cutoffs for quintiles based on the distribution
of each analyte within controls separately for each cohort (NHS and
NHSII) to account for differences in the distribution of menopausal
status between studies. We used conditional logistic regression to
estimate the odds ratio (OR) and 95% conﬁdence interval (CI).
Multivariable analyses were adjusted for physical activity, body
mass index (BMI), total dietary vitamin D intake, OC use, parity,
menopause status (include type of menopause), cohort, and
smoking because these variables have previously been associated
with CD or UC or may inﬂuence the levels of androgens. We did
not include use of nonsteroidal inﬂammatory drugs, appendectomy,
age at menarche, and age at menopause because these variables did
not alter our effect estimates. We also evaluated if the association
between androgens and risk of CD and UC varied by menopause
status (premenopausal or postmenopausal), current MHT (yes or
no), BMI (#25 or .25 kg/m2), and OC use (never or ever).
We used SAS version 9.3 (Cary, NC) for these analyses.
All P-values were 2-sided and ,0.05 was considered statistically
signiﬁcant.
RESULTS
Within both cohorts, our analysis included 83 cases of CD
matched to 165 controls and 91 cases of UC matched to 181
controls with prediagnostic blood specimens (Table 1). The
mean time between blood collection and diagnosis of either
CD or UC or index date for controls was 5.0 years
(SD ¼ 5.1). At the time of blood collection, the age range was
36 to 68 years for the CD case–control set and 36 to 69 years for
the UC case–control set. There were no signiﬁcant differences in
baseline characteristics of CD and UC cases with their matched
controls (Table 1). The median concentration of testosterone was
signiﬁcantly lower in CD cases (16.0 ng/dL) compared with
controls (19.0 ng/dL, Pdifference ¼ 0.01) (Table 1). There were
no signiﬁcant differences in plasma concentration of SHBG and
DHEAS comparing cases of CD with controls (all Pdifference .
0.30). Comparing UC cases with their matched controls, there
were no signiﬁcant differences in plasma concentrations of any
androgens (all Pdifference . 0.40).
Compared with matched controls, the risk of CD decreased
with higher plasma levels of testosterone (Ptrend ¼ 0.004)
(Table 2). Speciﬁcally, compared with the lowest quintile of
plasma levels of testosterone, the multivariable-adjusted ORs of
CD were 0.86 (95% CI, 0.39–1.90) for the second quintile, 0.49
(95% CI, 0.21–1.15) for the third quintile, 0.22 (95% CI, 0.08–
0.65) for the fourth quintile, and 0.39 (95% CI, 0.16–0.99) for the
highest quintile (Table 2). Although the risk of CD seemed to
decrease with higher plasma levels of SHBG, the trend did not
reach statistical signiﬁcance (Ptrend ¼ 0.11). We also evaluated the
effect of total plasma testosterone on risk of CD using plasma
testosterone as a continuous variable and found that for every 10
ng/mL increase in plasma levels of testosterone, the risk of CD
decreases by 15% (OR, 0.85; 95% CI, 0.74–0.97).
As the level of free testosterone is strongly inﬂuenced
by SHBG, the inverse association between testosterone and risk
of CD was signiﬁcantly attenuated in analysis of free testos-
terone, calculated from SHBG and total testosterone, and risk
of CD (Ptrend ¼ 0.24). In addition, we did not ﬁnd an associ-
ation between plasma levels of DHEAS (Ptrend ¼ 0.46) and risk
of CD.
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We explored the possibility that changes in endogenous
hormones due to subclinical disease may explain our observed
association. Thus, we repeated our analyses after excluding cases
of CD in whom blood samples were collected less than 2 years
before diagnosis. Compared with women in the lowest quintile of
plasma testosterone level, the multivariable-adjusted ORs of CD
were 0.68 (95% CI, 0.24–1.89) among women in the second
quintile, 0.24 (95% CI, 0.07–0.84) among women in the third
quintile, 0.10 (95% CI, 0.02–0.49) among women in the fourth
quintile, and 0.42 (95% CI, 0.14–1.27) among women in the
highest quintile (Ptrend ¼ 0.02).
In contrast, plasma levels of testosterone or free testoster-
one were not associated with risk of UC (Ptrend ¼ 0.84 and 0.25,
respectively) (Table 3). Although, the risk of UC seemed to
increase with increasing plasma levels of SHBG, the trend did
not reach statistical signiﬁcance (Ptrend ¼ 0.09). Compared with
the women in the lowest quintile of plasma levels of SHBG, the
multivariable-adjusted ORs of UC were 1.00 (95% CI, 0.44–2.28)
among women in the second quintile, 1.43 (95% CI, 0.55–3.69)
among women in the third quintile, 1.01 (95% CI, 0.39–2.58)
among women in the fourth quintile, and 2.80 (95% CI, 1.05–
7.49) among women in the highest quintile. We did not ﬁnd an
association between plasma levels of DHEAS (Ptrend ¼ 0.41) and
risk of UC.
We explored the possibility that the association of testos-
terone with risk of CD may be modiﬁed by other putative risk
factors (Table 4). The association of plasma testosterone and risk
of CD did not seem to be modiﬁed by OC use, menopausal status,
or BMI (all Pinteractions . 0.30). Although the effect of circulating
testosterone on risk of CD seemed to be modiﬁed by use of MHT,
a formal statistical test for interaction did not reach statistical
signiﬁcance (Pinteraction ¼ 0.06). Speciﬁcally, among postmeno-
pausal women who were not using MHT at the time of blood
draw, the multivariable-adjusted OR of CD for every 10 ng/dL
increase in testosterone was 0.66 (95% CI, 0.45–0.95). In con-
trast, among postmenopausal women who were using MHT at the
time of blood collection, the multivariable-adjusted OR of CD for
every 10 ng/dL increase in testosterone was 1.17 (95% CI, 0.88–
1.56). As levels of endogenous testosterone changes signiﬁcantly
with age, we also assessed whether the effect of testosterone on
risk of CD varies according to age as a continuous variable and
observed no effect modiﬁcation (Pinteraction ¼ 0.62). We could not
TABLE 1. Baseline Characteristics of Cases and Controls at the Time of Blood Collectiona
CD UC
Cases (N ¼ 83) Controls (N ¼ 165) Pdifferenceb Cases (N ¼ 91) Controls (N ¼ 181) Pdifferenceb
Cohort (%)c
NHS 71 71 0.98 65 65 0.97
NHSII 29 29 35 35
Age (yrs), mean (SD)c 53 (8) 53 (8) 0.99 52 (8) 52 (8) 0.92
BMI (kg/m2) 24.4 (4.9) 25.1 (5.3) 0.20 25.5 (5.1) 24.5 (5.3) 0.11
Physical activity (Met-h/wk) 11.1 (17.4) 10.6 (15.6) 0.58 10.3 (17.2) 11.0 (17.2) 0.51
Smoking (%) 0.34 0.58
Never 48 56 37 47
Past 35 33 48 44
Current 17 11 15 9
OC use (%) 59 65 0.33 71 65 0.34
Premenopause (%)c 31 32 1.00 37 38 1.00
MHT (%)d
Never 47 46 40 41
Past 35 36 40 40
Current 18 18 20 19
Parity 2.0 (1.6) 3.0 (1.8) 0.07 3.0 (1.7) 3.0 (1.6) 0.43
Vitamin D intake (IU/d) 300 (231) 324 (267) 0.30 293 (238) 298 (226) 0.87
Testosterone (ng/dL) 16.0 (10.8) 19.0 (13.4) 0.01 20.0 (10.2) 19.0 (9.0) 0.85
SHBG (nmol/L) 57.7 (52.7) 65.7 (46.4) 0.36 66.7 (53.7) 64.6 (40.9) 0.42
DHEAS (mg/dL) 57.0 (38.2) 63.0 (52.3) 0.99 62.0 (49.6) 62.0 (56.6) 0.53
aUnless otherwise noted, variables are presented as median.
bPdifference was estimated by chi-square test for categorical variables and Wilcoxon rank sum test for contiguous variables.
cMatching factor.
dRepresents percentages among postmenopausal women.
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TABLE 2. Risk of CD According to Quintiles of Plasma Androgen Concentrations
Q1 Q2 Q3 Q4 Q5 Ptrend
a
Testosterone (ng/dL)
Median (range), NHS 10 (7–11) 13 (12–15) 17 (16–19) 23 (20–25) 33 (26–64)
Median (range), NHSII 12 (10–15) 19 (17–20) 22 (21–25) 31 (26–34) 50 (35–99)
Cases/controls 23/31 24/36 16/34 7/30 13/33
Unadjusted OR 1.00 0.88 (0.41–1.87) 0.61 (0.27–1.36) 0.32 (0.12–0.85) 0.52 (0.22–1.24) 0.02
Adjusted ORb 1.00 0.86 (0.39–1.90) 0.49 (0.21–1.15) 0.22 (0.08–0.65) 0.39 (0.16–0.99) 0.004
DHEAS (mg/dL)
Median (range), NHS 16 (15–23) 37 (24–45) 53 (46–62) 72 (63–87) 102 (88–210)
Median (range), NHSII 53 (19–56) 66 (61–75) 90 (76–106) 133 (117–163) 197 (167–329)
Cases/controls 21/31 18/36 17/32 11/33 16/32
Unadjusted OR 1.00 0.72 (0.30–1.72) 0.78 (0.35–1.75) 0.51 (0.21–1.20) 0.74 (0.30–1.83) 0.30
Adjusted ORb 1.00 0.55 (0.22–1.38) 0.68 (0.29–1.60) 0.41 (0.16–1.09) 0.83 (0.32–2.20) 0.46
SHBG (nmol/L)
Median (range), NHS 29.1 (17.3–38.1) 46.8 (39.8–53.5) 64.3 (55.9–77.3) 89.5 (77.4–120.0) 143.0 (124.0–278.0)
Median (range), NHSII 24.4 (4.8–34.6) 44.7 (35.0–56.6) 66.1 (57.8–71.1) 80.4 (72.1–89.8) 131.0 (91.0–197.0)
Cases/controls 22/33 15/33 18/34 11/33 17/32
Unadjusted OR 1.00 0.68 (0.30–1.51) 0.81 (0.37–1.77) 0.50 (0.21–1.17) 0.75 (0.32–1.80) 0.33
Adjusted ORb 1.00 0.48 (0.20–1.15) 0.51 (0.21–1.27) 0.25 (0.08–0.73) 0.53 (0.20–1.41) 0.11
aPtrend was estimated by entering the median value of testosterone for each quintile category.
bAdjusted for BMI (in kilogram per square meter), cohort (NHS, NHSII), smoking (never, past, current), cumulative physical activity (MET-h/wk), total vitamin D intake (in international
units per day), parity, menopause status (premenopause, natural menopause, or menopause from surgery), MHT (never, past, or current), and OC use (never, ever).
TABLE 3. Risk of UC According to Quintiles of Plasma Androgen Concentrations
Q1 Q2 Q3 Q4 Q5 Ptrend
a
Testosterone (ng/dL)
Median (range), NHS 10 (7–11) 13 (12–15) 17 (16–19) 23 (20–25) 33 (26–64)
Median (range), NHSII 12 (10–15) 19 (17–20) 22 (21–25) 31 (26–34) 50 (35–99)
Cases/controls 22/32 17/43 17/33 12/36 23/37
Unadjusted OR 1.00 0.53 (0.23–1.24) 0.70 (0.31–1.61) 0.48 (0.20–1.14) 0.84 (0.37–1.89) 0.75
Adjusted ORb 1.00 0.63 (0.26–1.52) 0.81 (0.34–1.92) 0.55 (0.22–1.34) 0.91 (0.39–2.13) 0.84
DHEAS (mg/dL)
Median (range), NHS 16 (15–23) 37 (24–45) 53 (46–62) 72 (63–87) 102 (88–210)
Median (range), NHSII 53 (19–56) 66 (61–75) 90 (76–106) 133 (117–163) 197 (167–329)
Cases/controls 22/36 12/37 23/36 17/37 17/35
Unadjusted OR 1.00 0.55 (0.24–1.24) 1.05 (0.51–2.16) 0.75 (0.34–1.67) 0.79 (0.34–1.82) 0.75
Adjusted ORb 1.00 0.50 (0.21–1.15) 0.95 (0.45–2.01) 0.62 (0.27–1.45) 0.62 (0.26–1.52) 0.41
SHBG (nmol/L)
Median (range), NHS 29.1 (17.3–38.1) 46.8 (39.8–53.5) 64.3 (55.9–77.3) 89.5 (77.4–120.0) 143.0 (124.0–278.0)
Median (range), NHSII 24.4 (4.8–34.6) 44.7 (35.0–56.6) 66.1 (57.8–71.1) 80.4 (72.1–89.8) 131.0 (91.0–197.0)
Cases/controls 16/35 18/37 18/36 13/37 26/36
Unadjusted OR 1.00 1.05 (0.47–2.31) 1.17 (0.49–2.82) 0.79 (0.33–1.89) 1.93 (0.79–4.70) 0.35
Adjusted ORb 1.00 1.00 (0.44–2.28) 1.43 (0.55–3.69) 1.01 (0.39–2.58) 2.80 (1.05–7.49) 0.09
aPtrend was estimated by entering the median value of testosterone for each quintile category.
bAdjusted for BMI (in kilogram per square meter), cohort (NHS, NHSII), smoking (never, past, current), cumulative physical activity (MET-h/wk), total vitamin D intake (in international
units per day), parity, menopause status (premenopause, natural menopause, or menopause from surgery), MHT (never, past, or current), and OC use (never, ever).
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evaluate the possibility that smoking may modify the effect of
androgens on risk of CD due to low number of CD cases among
smokers (n ¼ 13). However, among never smokers, the
multivariable-adjusted OR of CD for every 10 ng/dL increase in
testosterone was 0.63 (95% CI, 0.48–0.83). The association of
testosterone on risk of UC did not vary by menopausal status,
BMI, or use of MHT or OCs (Table 4).
DISCUSSION
In this large, prospective, nested case–control study, we
observed that higher levels of prediagnostic plasma testosterone
are associated with lower risk of CD but not UC. In addition,
there was a suggestion that the association was more evident
among individuals who did not concurrently use MHT. There
was also a trend for a direct association between plasma levels of
SHBG and risk of UC as well as an inverse association between
plasma levels of SHBG and risk of CD. To our knowledge, no
previous study has investigated the link between endogenous
levels of plasma androgens and risk of CD and UC. A previous
study from our cohort has shown an association between OC use
and risk of CD, which has been supported by many other stud-
ies.8,9 OC use has been shown to reduce endogenous levels of
testosterone.11,13 Thus, the consistent association of OC and risk
of incident CD may be mediated by the biological consequences
of lower circulating testosterone. Moreover, the apparent beneﬁt
of higher circulating testosterone on risk of CD may be attenu-
ated by the use of high doses of exogenous estrogen in the form
of MHT.
Although our understanding of the pathogenesis of CD and
UC remains incomplete, the discovery of distinct genetic
susceptibility loci for both diseases points to potential diverging
biological pathways that may be differentially inﬂuenced by
endogenous levels of testosterone.5 In addition, CD and UC have
immunologically distinct gastrointestinal mucosal cytokine pro-
ﬁles, with mucosal inﬂammation in CD primarily mediated by
Th1-related cytokines and UC mediated by Th2-related cytokines.
The potential differential effect of sex hormones including estro-
gen and testosterone on Th1- and Th2-mediated disease processes
may partially explain the speciﬁc link between endogenous tes-
tosterone and risk of CD. In particular, testosterone has been
shown to modulate immune function, including cytokine produc-
tion. In animal models, endogenous levels of testosterone are
linked to reduction in expression of Toll-like receptor 4 on macro-
phages, which play a fundamental role in pathogen recognition
and innate immunity.15 In addition, recent animal data suggest
that gut commensal microbes may modulate levels of endogenous
testosterone, leading to development of autoimmune diseases.14
Thus, our observed association between endogenous testosterone
and development of CD may be biologically mediated by a com-
plex interaction between endogenous hormones, the gut micro-
biome, and immune function.
TABLE 4. Risk of CD and UC According to Plasma Testosterone Concentrations in Selected Strataa
CD UC
Cases/Controls MV-adjustedb Pinteraction Cases/Controls MV-adjusted
b Pinteraction
Cohorts
NHS + NHSII 83/164 0.85 (0.74–0.97) 0.64 91/181 1.03 (0.89–1.19) 0.33
NHS 59/116 0.86 (0.72–1.02) 59/117 1.08 (0.89–1.31)
NHSII 24/48 0.77 (0.57–1.02) 32/64 0.90 (0.69–1.17)
Menopausal status at blood collection 0.56 0.64
Premenopausal 26/52 0.74 (0.54–1.02) 34/68 1.05 (0.83–1.31)
Postmenopausal 47/92 0.87 (0.74–1.03) 46/91 1.01 (0.82–1.25)
MHT at blood collection 0.06 0.86
No 27/52 0.66 (0.45–0.95) 23/46 0.94 (0.61–1.43)
Yes 20/40 1.17 (0.88–1.56) 23/45 0.94 (0.65–1.37)
OC use 0.76 0.86
Never 34/56 0.83 (0.61–1.13) 26/62 1.07 (0.73–1.58)
Ever 49/108 0.78 (0.62–0.97) 65/119 0.89 (0.73–1.08)
BMI 0.39 0.07
,25 kg/m2 47/80 0.86 (0.66–1.11) 43/98 1.28 (0.93–1.76)
$25 kg/m2 36/84 0.76 (0.55–1.06) 48/83 0.81 (0.59–1.13)
aORs are calculated for every 10 ng/dL increase in plasma levels of testosterone.
bAdjusted for age (in years), BMI (in kilogram per square meter), cohort (NHS, NHSII), smoking (never, past, current), cumulative physical activity (Metabolic Equivalent of Task-h/wk),
total vitamin D intake (in international units per day), parity, fasting status, month of blood draw, menopausal status (premenopause, nonuser of MHT, current user of MHT) and OC use
(never, ever).
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Previously, we have shown an association between MHT
and increased risk of UC.10 Although the exact biological mech-
anism of this is unknown, estrogen compounds modify colonic
barrier function,30,31 which is a biological pathway that may be
uniquely related to pathogenesis of UC.32 Thus, modiﬁcation of
distinct biological processes by OC use compared with MHT may
have potentially divergent effects on the pathogenesis of CD and
UC. Of note, the apparent lack of association between free tes-
tosterone and risk of CD in our study is likely explained by the
signiﬁcant inﬂuence of plasma levels of SHBG on free testoster-
one levels, with higher SHBG levels being associated with lower
free testosterone.
Our study has several notable strengths. First, the
availability of detailed and validated information on BMI, use
of OC or MHT, physical activity, smoking, and other reproduc-
tive factors allowed us to control for a number of potential
confounders that may affect our observed associations. Second,
we have conﬁrmed all of the cases of CD and UC through
medical record review, an advantage over studies that rely on
self-reported or diagnoses codes that may not be accurate. Third,
blood samples were collected before diagnosis of CD and UC,
allowing us to assess prediagnosis levels of androgens in relation
to risk of disease.
We acknowledge several limitations. First, plasma levels
of androgens were based on a single measurement that may not
be an accurate reﬂection of long-term endogenous androgen
levels. However, the intraclass correlation over 3 years for these
androgens in luteal phase ranged from 0.73 (for testosterone) to
0.89 (for SHBG and DHEAS) in premenopausal women33 and
from 0.88 (for testosterone and DHEAS) to 0.92 (for SHBG) in
postmenopausal women,34 suggesting that a single measurement
reasonably reﬂects long-term levels. Second, unlike NHSII,
blood samples collected from premenopausal women in NHS
were not timed according to menstrual phase (luteal versus fol-
licular). However, androgen levels do not vary substantially by
menstrual phase.35,36 In addition, our ﬁndings were consistent
across the 2 cohorts of NHS and NHSII, and premenopausal
cases accounted for only 30% of all cases and controls. Third,
we acknowledge that because of our small number of cases, we
had limited power to detect more modest associations (e.g.,
SHBG). In addition, because of our sample size, the results from
our stratiﬁed analyses that endogenous levels of androgens may
modulate the effect of exogenous hormones on risk of CD
should be interpreted with caution. Finally, only 10 participants
(controls and cases) were taking OCs at the time of blood col-
lection and therefore we were unable to fully evaluate the
hypothesis that OCs through modulating the endogenous level
of androgens alter risk of developing CD. We estimated that at
least 40% of our participants would have had to be on OCs at the
time of blood collection in order for us to have nearly 80%
power to detect the potential mediation effect of testosterone
on the associations between OCs and risk of CD.
In conclusion, we show that prediagnosis levels of
circulating total testosterone are associated with a lower risk of
CD but not UC among women. This ﬁnding may, at least in part,
explain the consistent association observed between use of OC
and subsequent risk of CD. Although the exact mechanism
underlying the association between exogenous and endogenous
sex hormones and risk of CD is largely unknown, we believe that
these initial studies justify the need for further translational studies
carried out at the intersection of epidemiology, sex hormones, the
gut microbiome, and immune function. In particular, further
investigation into evaluating the complex interaction between
exogenous and endogenous sex hormones and community
structure of human gut microbiome on risk and progression of
CD are warranted. Finally, whether exogenous and endogenous
sex hormones also play a role in IBD progression is yet to be
determined and is the topic of future research.
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